Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAT deficiency

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

CytomX makes senior changes following Pfizer deal

Krishna Polu joins as chief medical officer and Debanjan Ray promoted to VP, business development

- PMLiVE

FDA panel fails to back new use for AbbVie’s Humira

Votes 12 to 1 against new use in spondyloarthritis

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

- PMLiVE

FDA approves intravenous Simponi for arthritis treatment

J&J says Simponi Aria will offer less frequent dosing schedule than subcutaneous version

- PMLiVE

FDA fast-tracks Elan’s Alzheimer’s drug

Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms

- PMLiVE

Pfizer wins Xeljanz approvals in five more countries

Switzerland, Argentina, Kuwait, United Arab Emirates and Russia to receive arthritis drug

- PMLiVE

AstraZeneca launches Nexium YouTube channel

New AZPurpleZone channel aimed at US patients with acid reflux disease offers symptom-relief advice and product savings

- PMLiVE

FDA clears first brain test to diagnose ADHD in children

NEBA system available as part of wider clinical assessment

National Institute for Health and Care Excellence NICE logo

Pfizer faces NICE rejection for cancer drug Bosulif

Draft guidance says drug is not cost-effective in chronic myeloid leukaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links